Skip to content

Collect Digital Data

Opportunity

Participants expect a simple and convenient experience participating on clinical trials. To accomplish this goal, sponsors should consider the type, design and delivery of device (e.g., personal device,  provided by study, etc.) for participants to achieve accessibility, flexibility, convenience and maintain privacy. 

Considerations to Help Action the Opportunity

  • Understand if the clinical trial design supports the applications of digital patient solutions
  • Understand the needs and preferences of the participants taking part in the trial
    • Does the population have access to devices and data plans, or would they need these to be provisioned?
    • What devices would participants already have that could be used for clinical trials (e.g., wearables / sensors, glucometers, weighing scales, phones / tablets, etc.​)?
    • Understand impact on health equity (i.e., geographic, socioeconomic barriers) when implementing digital solutions 
  • Partner with sites to gain their input on the impact of multiple services, training, and technology implementation
  • Understand how the device may impact data integrity, regulatory landscape, site implementation and overall costs  
  • Define how technology is designed, communicated and delivered for / to participants
  • Define backup options (e.g., when a participant is unable to connect to device)

Value and Potential Benefits

  • Increases access and ease of participation for participants on clinical trials by potentially reducing the number of site visits
  • Allows for more robust datasets with improved data compliance and quality by enabling direct entry and near real-time review of data

Related Blog Posts

A New Era in Advancing Care for Pregnant and Breastfeeding Patients

One major challenge facing the clinical research ecosystem is not whether, but how to study drug safety and efficacy in pregnant and breastfeeding populations. A growing number of organizations—including the ICH E21 Expert Working Group (EWG) and TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations  (IGR PV) initiative—are diligently seeking ethical and responsible solutions to protect these…

Improving Medicine Use During Pregnancy & Breastfeeding: Forging a Path Forward   

The scientific community intended to protect pregnant and breastfeeding populations when it strictly limited their involvement in clinical trials after the thalidomide crisis of the 1950s-1960s. Yet over the past few decades, people have increasingly recognized the real-life challenges posed by the lack of research into the safety of medications used during pregnancy and breastfeeding.…

Transforming Pharmacovigilance: Solutions to Solve Regulatory Challenges

Patient safety depends partly on sponsor organizations’ compliance with pharmacovigilance (PV) regulatory requirements—even when global variations exist. Helping sponsors interpret and operationalize challenging PV regulations and guidances is the goal of TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative. In this third installment of our IGR PV blog series, we will examine the solutions…